Cargando…
Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial
A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778427/ https://www.ncbi.nlm.nih.gov/pubmed/35062752 http://dx.doi.org/10.3390/vaccines10010092 |
_version_ | 1784637321581166592 |
---|---|
author | Sintusek, Palittiya Buranapraditkun, Supranee Wanawongsawad, Piyaporn Posuwan, Nawarat Thantiworasit, Pattarawat Wanlapakorn, Nasamon Klaewsongkram, Jettanong Suratannon, Narissara Chaijitraruch, Nataruks Chongsrisawat, Voranush Poovorawan, Yong |
author_facet | Sintusek, Palittiya Buranapraditkun, Supranee Wanawongsawad, Piyaporn Posuwan, Nawarat Thantiworasit, Pattarawat Wanlapakorn, Nasamon Klaewsongkram, Jettanong Suratannon, Narissara Chaijitraruch, Nataruks Chongsrisawat, Voranush Poovorawan, Yong |
author_sort | Sintusek, Palittiya |
collection | PubMed |
description | A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised. |
format | Online Article Text |
id | pubmed-8778427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87784272022-01-22 Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial Sintusek, Palittiya Buranapraditkun, Supranee Wanawongsawad, Piyaporn Posuwan, Nawarat Thantiworasit, Pattarawat Wanlapakorn, Nasamon Klaewsongkram, Jettanong Suratannon, Narissara Chaijitraruch, Nataruks Chongsrisawat, Voranush Poovorawan, Yong Vaccines (Basel) Article A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised. MDPI 2022-01-08 /pmc/articles/PMC8778427/ /pubmed/35062752 http://dx.doi.org/10.3390/vaccines10010092 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sintusek, Palittiya Buranapraditkun, Supranee Wanawongsawad, Piyaporn Posuwan, Nawarat Thantiworasit, Pattarawat Wanlapakorn, Nasamon Klaewsongkram, Jettanong Suratannon, Narissara Chaijitraruch, Nataruks Chongsrisawat, Voranush Poovorawan, Yong Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial |
title | Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial |
title_full | Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial |
title_fullStr | Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial |
title_full_unstemmed | Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial |
title_short | Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial |
title_sort | safety and immunogenicity of standard and double doses of hepatitis b vaccine in children after liver transplantation: an open-label, randomised controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778427/ https://www.ncbi.nlm.nih.gov/pubmed/35062752 http://dx.doi.org/10.3390/vaccines10010092 |
work_keys_str_mv | AT sintusekpalittiya safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT buranapraditkunsupranee safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT wanawongsawadpiyaporn safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT posuwannawarat safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT thantiworasitpattarawat safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT wanlapakornnasamon safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT klaewsongkramjettanong safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT suratannonnarissara safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT chaijitraruchnataruks safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT chongsrisawatvoranush safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial AT poovorawanyong safetyandimmunogenicityofstandardanddoubledosesofhepatitisbvaccineinchildrenafterlivertransplantationanopenlabelrandomisedcontrolledtrial |